Recombinant Human IL-33 Protein , N-His

Interleukin-33 (IL-33), a member of the IL-1 family of cytokines, has gained significant attention in immunology and inflammation research due to its diverse roles in immune responses and disease pathogenesis. It acts as an alarmin, being released by damaged or necrotic cells to activate innate immune pathways, particularly promoting the activation of Th2 cells and type 2 immune responses. This immunomodulatory function makes IL-33 a key player in various pathological conditions such as allergies, asthma, and autoimmune diseases. The recombinant form of IL-33 has been developed to explore its therapeutic potential and molecular mechanisms further. Researchers are investigating its ability to modulate immune cell functions, its signaling pathways, and its interaction with other cytokines. Additionally, studies are focusing on the role of IL-33 in promoting tissue remodeling and its implications in chronic inflammation. Understanding the precise functions and mechanisms of IL-33 could pave the way for novel therapeutic strategies targeting diseases characterized by dysregulated immune responses. As research progresses, IL-33 is being evaluated not only as a potential biomarker for disease but also as a therapeutic agent, offering promise in managing a spectrum of inflammatory and allergic conditions. Thus, the recombinant IL-33 protein is a vital tool in elucidating the complexities of immune regulation and holds promise for future clinical applications.